Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis

Eur J Med Chem. 2022 Aug 5:238:114423. doi: 10.1016/j.ejmech.2022.114423. Epub 2022 May 8.

Abstract

Sepsis has long been a major health problem worldwide. It threatens the lives of hospitalized patients and has been one of the leading causes of death in hospitalized patients over the past decades. BRD4 has been regarded as a potential target for sepsis therapy, for its critical role in the transcriptional expression of NF-κB pathway-dependent inflammatory factors. In this study, compound 1 was obtained through virtual screening, and candidate compound 27 was obtained through several rounds of iterative SAR analysis. 27 decreased LPS-induced NO production and expression of the pro-inflammatory factors IL-6, IL-1β and TNF-α. In vivo, 27 effectively protected mice from LPS-induced sepsis, increased survival rate and decreased the level of pro-inflammatory factors in serum. Collectively, we reported here 27, a BRD4 inhibitor with a new scaffold, as a potential candidate for the treatment of sepsis.

Keywords: BET; BRD4 inhibitor; Bromodomain; Sepsis.

MeSH terms

  • Animals
  • Cell Cycle Proteins* / antagonists & inhibitors
  • Humans
  • Lipopolysaccharides
  • Mice
  • NF-kappa B / metabolism
  • Nuclear Proteins*
  • Sepsis* / drug therapy
  • Transcription Factors* / antagonists & inhibitors

Substances

  • BRD4 protein, human
  • Cell Cycle Proteins
  • Lipopolysaccharides
  • NF-kappa B
  • Nuclear Proteins
  • Transcription Factors